Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

LY3463251

DISCONTINUED

Long-acting GDF15 receptor agonist acting through GFRAL and RET

1
graded results
0
ongoing records
1
effect domains
Evidence spread
High evidence 0Moderate evidence 0Low evidence 1Very low evidence 0

LY3463251 has a discontinued status in the scoped regulatory record below. Results describe observations and do not provide treatment advice.

Dated status sources

DISCONTINUED Global programme; Obesity phase 1 programme (NCT03764774); Subcutaneous injection; as of 2026-07-13. ClinicalTrials.gov

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
LY3463251 DISCONTINUED
pharmacology Decrease
Low evidence

Proof-of-mechanism: in overweight/obese participants, 12-week multiple-ascending-dose LY3463251 significantly reduced food intake and appetite scores independent of...

Benichou et al., Cell Metab 2023 (LY3463251 discovery and clinical proof of mechanism) Source
Full findingProof-of-mechanism: in overweight/obese participants, 12-week multiple-ascending-dose LY3463251 significantly reduced food intake and appetite scores independent of nausea/emesis, but produced only modest body-weight reduction. The GDF15 axis suppresses appetite without the expected weight magnitude, a challenge for clinical weight-loss use.
PopulationPhase 1 multiple-ascending-dose, 12 weeks, healthy and overweight/obese participants, placebo-controlled
Fundingindustry - Eli Lilly (trial sponsor; inferred from registration trial)
Comparatorsplacebo